NCT06439550View on ClinicalTrials.gov

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
HER2-positive Gastric Cancer
Interventions
DRUG

Serplulimab

300mg, q3w

DRUG

Trastuzumab

First dose 8mg/kg, maintenance 6mg/kg, q3w

DRUG

Oxaliplatin + Tegafur

oxaliplatin (130mg/m2, q3w) + Tegafur (40mg/m2, bid d1-d14, q3w).

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER

NCT06439550 - Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC | Biotech Hunter | Biotech Hunter